BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:lacutamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of lacutamab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04984837-10946@assetmemo.bio
DTSTAMP:20261121T005842Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:lacutamab: Phase 2 readout est. (NCT04984837)
DESCRIPTION:lacutamab\, phase 2.\nStudy: Study of Lacutamab in Peripheral T
 -cell Lymphoma\nEstimated primary completion: 30 April 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/lacutamab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04984837
URL:https://assetmemo.bio/drug/lacutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
